Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients

Br J Haematol. 2013 Feb;160(4):561-4. doi: 10.1111/bjh.12139. Epub 2012 Dec 4.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Combined Modality Therapy / methods
  • Dexamethasone / administration & dosage
  • Disease-Free Survival
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Middle Aged
  • Multiple Myeloma / therapy*
  • Prospective Studies
  • Pyrazines / administration & dosage
  • Remission Induction
  • Transplantation, Autologous
  • Young Adult

Substances

  • Boronic Acids
  • Pyrazines
  • Bortezomib
  • Dexamethasone